The price tag will be $54 per share, which corresponds to a market capitalization of $4.7 billion, approximately 44 billion Swedish kronor, according to a press release from Novo Nordisk.
In recent years, Novo Nordisk has become best known for the weight loss drugs Wegovy and Ozempic, which have made the company one of Europe's largest by market capitalization.
